Differences in Driving Outcomes Among Cognitively Normal African American and Caucasian Older Adults
- 12 Downloads
To examine the effect of race in driving performance and behavior prospectively among cognitively normal older adults.
Cognitively normal participants (Clinical Dementia Rating 0), ≥ 65 years of age (n = 177) were selected from prospective, longitudinal studies at the Knight Alzheimer Disease Research Center at Washington University. Self-reported driving behavior (Driving Habits Questionnaire) and driving performance (road test) were annually assessed. Daily driving behavior data were collected using the Driving Real World In-Vehicle Evaluation System (DRIVES). Baseline differences between African Americans and Caucasians were tested using t tests and general linear models. Amyloid imaging and cerebrospinal fluid Alzheimer disease (AD) biomarkers were compared across groups. Linear mixed models examined change in daily driving behavior over time. Survival analyses tested time to a marginal or fail rating on the road test.
There were no differences between African Americans (n = 34) and Caucasians (n = 143) in age, sex, education, or vascular risk factors. Baseline self-reported driving behavior and road test performance were largely similar for both races. Longitudinal analyses using the DRIVES data aggregated monthly showed that African Americans had a greater reduction in number of trips made per month, miles driven per month, and trips with aggressive behavior compared to Caucasians. These effects remained after controlling for AD biomarkers, age, education, and sex.
In this sample of cognitively normal older adults, African Americans had a greater reduction of daily driving behavior compared to Caucasians. Observed racial differences may reflect differences in environmental/social factors, changes in cognition, and/or physical functioning.
KeywordsAlzheimer’s disease African Americans Older adults Driving Race
The authors thank the participants, investigators/staff of the Knight ADRC Clinical, Biomarker, Genetics, and Neuroimaging Cores, and the investigators/staff of the Driving Performance in Preclinical Alzheimer’s Disease study (R01-AG056466).
Study concept and design (GB, CR), data acquisition (GM, GR, BA, CR), data analysis (GB, GR, CR), and interpretation (GB, GR, SS, MW, JV, AH, MZ, BA, CR), drafting (GB, CR), and critical revision of manuscript (GB, GR, SS, MW, JV, AH, MZ, TLSB, JCM, BA, CR).
Funding for this study was provided by the Alzheimer’s Association [AARFD-16-439140]; the National Institute on Aging [R03-AG055482, R01-AG056466, R01-AG043434, R01-AG43434-03S1, P50-AG05681, P01-AG03991, P01-AG026276, R01-AG057680]; University Research Strategic Alliance [URSA] 2016; Fred Simmons and Olga Mohan, Paula and Rodger O. Riney Fund, the Brennan Fund, and the Charles and Joanne Knight Alzheimer’s Research Initiative of the Washington University Knight Alzheimer’s Disease Research Center (ADRC).
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Washington University Human Research Protection Office ) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of Interest
Dr. Babulal reports no disclosures or conflicts. Ms. Stout reports no disclosures. Dr. Williams reports no disclosures. Mr. Rajasekar reports no disclosures. Dr. Harmon reports no disclosures. Dr. Vivoda reports no disclosures. Dr. Zuelsdorff reports no disclosures. Dr. Benzinger is funded by NIH grants # P50AG005681; UF1AG032438; U01AG042791; 2P01AG003991; P01AG026276; R01AG043434; U54 MH091657; and the Barnes-Jewish Hospital Foundation. Dr. Benzinger reports no conflicts of interest. Dr. Morris and his family do not own stock or have equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Dr. Morris has participated or is currently participating in clinical trials of antidementia drugs sponsored by the following companies: Janssen Immunotherapy, Pfizer, Eli Lilly/Avid Radiopharmaceuticals, SNIFF (The Study of Nasal Insulin to Fight Forgetfullness) study, and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) trial. Dr. Morris has served as a consultant for Lilly USA, and Charles Dana Foundation. He receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded by NIH grants # P50AG005681; P01AG003991; P01AG026276 and UF1AG032438. Dr. Morris reports no conflicts of interest. Dr. Ances reports no disclosures. Dr. Roe reports no disclosures.
- 1.Colby SL, Ortman JM. Projections of the size and composition of the US population: 2014 to 2060: Population estimates and projections 2017.Google Scholar
- 2.Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. Washington, DC: US Census Bureau; 2014. p. 25–1140.Google Scholar
- 4.The Federal Interagency Forum on Aging-Related Statistics. Older Americans 2016: key indicators of well-being. Federal Interagency Forum on Aging-Related Statistics. 2016.Google Scholar
- 5.National Center for Statistics and Analysis. 2015 older population fact sheet. Washington, DC: National Highway Traffic Safety Administration. 2017.Google Scholar
- 6.National Highway Traffic Safety Administration. Traffic Safety Facts 2012 data: older population. 2014.Google Scholar
- 7.Insurance Institute for Highway Safety. Fatality facts 2013, Older people 2014. http://www.iihs.org/iihs/topics/t/older-drivers/fatalityfacts/older-people/2013.
- 12.Centers for Disease Control Prevention. Web-based Injury Statistics Query and Reporting System (WISQARS). In: National Center for Injury Prevention and Control, CDC. 2017. https://www.cdc.gov/motorvehiclesafety/older_adult_drivers/index.html. 2017.
- 21.Iverson DJ, Gronseth GS, Reger MA, Classen S, Dubinsky RM, Rizzo M. Practice parameter update: evaluation and management of driving risk in dementia report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(16):1316–24.PubMedPubMedCentralCrossRefGoogle Scholar
- 23.Hird MA, Egeto P, Fischer CE, Naglie G, Schweizer TA. A systematic review and meta-analysis of on-road simulator and cognitive driving assessment in Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis. 2016(Preprint):1-17.Google Scholar
- 24.Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, et al. Amyloid imaging, cerebrospinal fluid biomarkers predict driving performance among cognitively normal individuals. Alzheimer Dis Assoc Disord. 2017;31(1):69–72. https://doi.org/10.1097/wad.0000000000000154.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Ott BR, Jones RN, Noto RB, Yoo DC, Snyder PJ, Bernier JN, et al. Brain amyloid in preclinical Alzheimer’s disease is associated with increased driving risk. Alzheimers Dement. 2017;6:136–42.Google Scholar
- 27.Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, et al. Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need. Alzheimers Dement. 2018. https://doi.org/10.1016/j.jalz.2018.09.009.CrossRefGoogle Scholar
- 28.Centers for Disease C, Prevention. Health disparities experienced by black or African Americans--United States. MMWR Morb Mortal Wkly Rep. 2005;54(1):1-3.Google Scholar
- 36.Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993.Google Scholar
- 39.Goodglass H, Kaplan E. Boston Naming Test: scoring booklet: Lea & Febiger; 1983.Google Scholar
- 44.Fagan AM, Mintun MM, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med. 2009;1(8-9):371–80.PubMedPubMedCentralCrossRefGoogle Scholar
- 55.Dugan E, Lee CM. Biopsychosocial risk factors for driving cessation findings from the health and retirement study. J Aging Health. 2013;0898264313503493.Google Scholar
- 58.Seelye A, Mattek N, Sharma N, Witter IV, Brenner A, Wild K, et al. Passive assessment of routine driving with unobtrusive sensors: a new approach for identifying and monitoring functional level in normal aging and mild cognitive impairment. J Alzheimers Dis. 2017;59(4):1427–37.PubMedPubMedCentralCrossRefGoogle Scholar
- 59.Paire-Ficout L, Lafont S, Conte F, Coquillat A, Fabrigoule C, Ankri J, et al. Naturalistic Driving study investigating self-regulation behavior in early Alzheimer’s disease: a pilot study. J Alzheimers Dis. 2018(Preprint:1–10.Google Scholar
- 64.Gleason CE, Norton D, Zuelsdorff M, Benton SF, Wyman MF, Nystrom N, et al. Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer’s Disease Center. Alzheimer’s & Dementia: Alzheimers Dement. 2019.Google Scholar